Compare PRPL & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPL | ANIX |
|---|---|---|
| Founded | 2010 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.8M | 135.3M |
| IPO Year | N/A | 1987 |
| Metric | PRPL | ANIX |
|---|---|---|
| Price | $0.82 | $3.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.00 | ★ $9.00 |
| AVG Volume (30 Days) | 300.7K | ★ 353.5K |
| Earning Date | 11-04-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $457,012,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $2.07 |
| 52 Week High | $1.29 | $5.46 |
| Indicator | PRPL | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 36.66 |
| Support Level | $0.73 | $4.20 |
| Resistance Level | $0.86 | $5.46 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 74.04 | 3.40 |
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.